| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Yakkasterone targets the glucocorticoid receptor (GR), a nuclear receptor that regulates gene transcription in response to glucocorticoids. As a GR ligand, it modulates GR-mediated signaling pathways. It also inhibits cholesterol synthesis with an IC₅₀ of 350 nM, suggesting additional effects on lipid metabolism.
|
|---|---|
| ln Vitro |
5α-Hydroxy-6-keto cholesterol (0.01, 0.1, 1, 10 μM) is harmful to 16-HBE cells in vitro [1].
In vitro, Yakkasterone (5α-hydroxy-6-keto cholesterol) inhibits cholesterol synthesis with an IC₅₀ of 350 nM. It is a metabolite of β-epoxide (5α,6β-epoxycholesterol) produced during ozone exposure of human bronchial epithelial cells. The compound exhibits cytotoxic properties. |
| ln Vivo |
In vivo activity data for Yakkasterone are limited in the available literature. As a cholesterol-derived metabolite and GR ligand, it has potential applications in studying cholesterol metabolism, oxidative stress, and glucocorticoid receptor signaling. Its role as an oncometabolite has been identified, suggesting potential relevance in cancer research.
|
| Enzyme Assay |
In vitro receptor binding assays for Yakkasterone are performed using purified glucocorticoid receptor (GR) protein. Binding affinity is measured using radioligand competition binding assays or fluorescence polarization. Functional assays measure GR-mediated transcriptional activity using reporter gene assays in cells expressing the receptor.
|
| Cell Assay |
In vitro cellular assays for Yakkasterone are performed using human bronchial epithelial cells (16-HBE) or other cell lines. Cells are treated with the compound, and cholesterol synthesis is measured by incorporating radiolabeled acetate or by quantifying cholesterol levels. Cytotoxicity is assessed using standard viability assays.
|
| Animal Protocol |
In vivo animal experiments for Yakkasterone are not extensively documented. As a research compound, in vivo studies would typically involve administration to animal models to study cholesterol metabolism, oxidative stress, or glucocorticoid receptor signaling. The compound would be administered via appropriate routes, and efficacy would be assessed by measuring cholesterol levels, inflammatory markers, and GR target gene expression.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Yakkasterone have not been systematically characterized. The compound has a molecular weight of 418.7 and molecular formula C₂₇H₄₆O₃. Its chemical name is 3β,5α-dihydroxycholestan-6-one. It has a UNII of YO7G6S09N3. Further PK studies are needed to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Yakkasterone are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Melissa K Pulfer, et al. Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant. J Biol Chem. 2004 Jun 18;279(25):26331-8.
|
| Additional Infomation |
Cholesterane-6-oxo-3,5-diol is a type of cholesterolane compound.
Yakkasterone is also known as 5α-hydroxy-6-keto cholesterol, 6-oxo-cholestan-3β,5α-diol (OCDO), and cholestane-6-oxo-3,5-diol. It is a cholesterol-derived metabolite, a GR ligand, and an inhibitor of cholesterol synthesis (IC₅₀ = 350 nM). It is used in metabolic and cancer research. This product is for research use only. |
| Molecular Formula |
C27H46O3
|
|---|---|
| Molecular Weight |
418.662
|
| Exact Mass |
418.344
|
| CAS # |
13027-33-3
|
| PubChem CID |
159461
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
528.9±45.0 °C at 760 mmHg
|
| Flash Point |
287.7±25.2 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.531
|
| LogP |
7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
659
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC(=O)[C@]4(C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O)O
|
| InChi Key |
SJZZRXMQSAXCFD-ZCBMJONGSA-N
|
| InChi Code |
InChI=1S/C27H46O3/c1-17(2)7-6-8-18(3)21-9-10-22-20-15-24(29)27(30)16-19(28)11-14-26(27,5)23(20)12-13-25(21,22)4/h17-23,28,30H,6-16H2,1-5H3/t18-,19+,20+,21-,22+,23+,25-,26-,27+/m1/s1
|
| Chemical Name |
(3S,5R,8S,9S,10R,13R,14S,17R)-3,5-dihydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-one
|
| Synonyms |
YS 64; Yakkasterone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3886 mL | 11.9429 mL | 23.8857 mL | |
| 5 mM | 0.4777 mL | 2.3886 mL | 4.7771 mL | |
| 10 mM | 0.2389 mL | 1.1943 mL | 2.3886 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
